Erasca ERAS Stock
Erasca Price Chart
Erasca ERAS Financial and Trading Overview
| Erasca stock price | 17.6 USD |
| Previous Close | 17.08 USD |
| Open | 17.28 USD |
| Bid | 12.71 USD x 200 |
| Ask | 22.13 USD x 200 |
| Day's Range | 17.21 - 17.82 USD |
| 52 Week Range | 1.33 - 24.28 USD |
| Volume | 2.45M USD |
| Avg. Volume | 4.87M USD |
| Market Cap | 6.17B USD |
| Beta (5Y Monthly) | 0.652 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.95 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 23.5 USD |
ERAS Valuation Measures
| Enterprise Value | 5.94B USD |
| Trailing P/E | N/A |
| Forward P/E | -29.517637 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 15.2245245 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -40.22 |
Trading Information
Erasca Stock Price History
| Beta (5Y Monthly) | 0.652 |
| 52-Week Change | 967.50% |
| S&P500 52-Week Change | 18.15% |
| 52 Week High | 24.28 USD |
| 52 Week Low | 1.33 USD |
| 50-Day Moving Average | 17.57 USD |
| 200-Day Moving Average | 12.01 USD |
ERAS Share Statistics
| Avg. Volume (3 month) | 4.87M USD |
| Avg. Daily Volume (10-Days) | 2.83M USD |
| Shares Outstanding | 349.76M |
| Float | 242.9M |
| Short Ratio | 6.33 |
| % Held by Insiders | 9.47% |
| % Held by Institutions | 85.77% |
| Shares Short | 29.95M |
| Short % of Float | 9.56% |
| Short % of Shares Outstanding | 8.63% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -21.39% |
| Return on Equity (ttm) | -78.24% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -147743008 USD |
| Net Income Avi to Common (ttm) | -287223008 USD |
| Diluted EPS (ttm) | -0.95 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 268.74M USD |
| Total Cash Per Share (mrq) | 0.77 USD |
| Total Debt (mrq) | 44.71M USD |
| Total Debt/Equity (mrq) | 12.36 USD |
| Current Ratio (mrq) | 8.294 |
| Book Value Per Share (mrq) | 1.158 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -98022000 USD |
| Levered Free Cash Flow (ttm) | -210460000 USD |
Profile of Erasca
| Country | United States |
| State | CA |
| City | San Diego |
| Address | 3115 Merryfield Row |
| ZIP | 92121 |
| Phone | 858 465 6511 |
| Website | https://www.erasca.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 103 |
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Q&A For Erasca Stock
What is a current ERAS stock price?
Erasca ERAS stock price today per share is 17.6 USD.
How to purchase Erasca stock?
You can buy ERAS shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Erasca?
The stock symbol or ticker of Erasca is ERAS.
Which industry does the Erasca company belong to?
The Erasca industry is Biotechnology.
How many shares does Erasca have in circulation?
The max supply of Erasca shares is 349.76M.
What is Erasca Price to Earnings Ratio (PE Ratio)?
Erasca PE Ratio is now.
What was Erasca earnings per share over the trailing 12 months (TTM)?
Erasca EPS is -0.95 USD over the trailing 12 months.
Which sector does the Erasca company belong to?
The Erasca sector is Healthcare.
Erasca ERAS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25980.19 USD — |
-0.76
|
6.45B USD — | 25910.82 USD — | 26109.96 USD — | — - | 6.45B USD — |
|
US Tech Global Select Market Com
NQGS
US
|
12752.65 USD — |
-0.75
|
— — | 12718.14 USD — | 12816.46 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
7248.1 USD — |
-0.51
|
— — | 7170.25 USD — | 7260.92 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1361.34 USD — |
-0.47
|
— — | 1351.98 USD — | 1363.95 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}
